The analysis of the Cancer Genome Atlas (TCGA) and public data revealed ACE-2 over-expression in many kinds of malignancies, including rectum adenocarcinoma, cervical cancer, pancreatic adenocarcinoma, kidney renal papillary cell carcinoma and kidney renal clear cell carcinoma, when compared with adjacent tissues, while ACE-2 downregulation was observed in liver, breast and prostate cancers [41]. The gene discussed is ACE2; the disease is prostate cancer.